Cufence

RSS

trientine dihydrochloride

Authorised
This medicine is authorised for use in the European Union.

Overview

Cufence is a medicine used to treat patients aged 5 years and older with Wilson's disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage. Cufence is used in patients who cannot take D-penicillamine, another medicine for this condition.
Cufence contains the active substance trientine dihydrochloride.

This EPAR was last updated on 04/03/2020

Authorisation details

Product details
Name
Cufence
Agency product number
EMEA/H/C/004111
Active substance
trientine dihydrochloride
International non-proprietary name (INN) or common name
trientine dihydrochloride
Therapeutic area (MeSH)
Hepatolenticular Degeneration
Anatomical therapeutic chemical (ATC) code
A16A
Publication details
Marketing-authorisation holder
Univar BV
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
25/07/2019
Contact address

Schouwburgplein 30
3012 CL
Rotterdam
Netherlands

Product information

30/01/2020 Cufence - EMEA/H/C/004111 - II/0002/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Other alimentary tract and metabolism products

Therapeutic indication

Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.

Assessment history

How useful was this page?

Add your rating